Structured evidence table for Nac Respiratory Symptoms Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Nac Respiratory Symptoms Randomized Trial | This document consolidates existing evidence to this effect, and adds insights from practicing clinicians to guide about use of NAC in clinical practice. | 2 | Barne M (2026) | N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR). |
| Nac Respiratory Symptoms Randomized Trial | Conclusion This consensus underscores the role of NAC in chronic respiratory diseases beyond its mucolytic properties and reiterates that NAC's antioxidant, anti-inflammatory, immunomodulatory and anti-biofilm properties provide significant clinical utility. | 2 | Barne M (2026) | N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR). |
| Nac Respiratory Symptoms Randomized Trial | While promising for TB and respiratory infections, further evidence is required. | 2 | Barne M (2026) | N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR). |
| Nac Respiratory Symptoms Randomized Trial | Background N-acetylcysteine (NAC) is a key precursor of glutathione (GSH), the lung's principal antioxidant. | 2 | Barne M (2026) | N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR). |
| Nac Respiratory Symptoms Randomized Trial | Recent translational data suggest that muco-obstructive lung diseases are typically associated with hyperconcentrated, i.e., dehydrated, mucus []. | 3 | Larobina Domenico (2026) | Mucoactive Agents in Muco-Obstructive Lung Diseases: A Critical Reappraisal of Pharmacological Effects and Clinical Outcomes |
| Nac Respiratory Symptoms Randomized Trial | First, electrophysiological studies suggest that imbalances in Na/fluid absorption versus Cl/fluid secretion cause increased mucus concentrations (). | 3 | Larobina Domenico (2026) | Mucoactive Agents in Muco-Obstructive Lung Diseases: A Critical Reappraisal of Pharmacological Effects and Clinical Outcomes |
| Nac Respiratory Symptoms Randomized Trial | This conformation is in part the result of the salt bridges mentioned previously. | 3 | Larobina Domenico (2026) | Mucoactive Agents in Muco-Obstructive Lung Diseases: A Critical Reappraisal of Pharmacological Effects and Clinical Outcomes |
| Nac Respiratory Symptoms Randomized Trial | 1 2 3 4 5 6 Appendix A Mucoactive agents are drugs that facilitate the clearance of airway secretions through a variety of mechanisms, including modification of mucus structure, hydration, and transport. | 3 | Larobina Domenico (2026) | Mucoactive Agents in Muco-Obstructive Lung Diseases: A Critical Reappraisal of Pharmacological Effects and Clinical Outcomes |
Source documents